PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT8085218

| SUBMISSION TYPE: | NEW ASSIGNMENT |
|-----------------------|----------------|
| NATURE OF CONVEYANCE: | ASSIGNMENT |

CONVEYING PARTY DATA

| Name | Execution Date |
|-----------------|----------------|
| JOHN DESJARLAIS | 09/16/2020 |
| ALEX NISTHAL | 09/08/2020 |
| SEUNG CHU | 09/02/2020 |

RECEIVING PARTY DATA

| Name: | XENCOR, INC. | |
|-----------------|-----------------------|--|
| Street Address: | 111 WEST LEMON AVENUE | |
| City: | MONROVIA | |
| State/Country: | CALIFORNIA | |
| Postal Code: | 91016 | |

PROPERTY NUMBERS Total: 1

| Property Type | Number |
|---------------------|----------|
| Application Number: | 17233083 |

CORRESPONDENCE DATA

Fax Number: (415)442-1001

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4154421000

Email: sfipdocketing@morganlewis.com, leonor.rivera@morganlewis.com

MORGAN, LEWIS & BOCKIUS, LLP **Correspondent Name:** Address Line 1: ONE MARKET, SPEAR STREET TOWER Address Line 4: SAN FRANCISCO, CALIFORNIA 94105

| ATTORNEY DOCKET NUMBER: | 067461-5219-US01 | |
|-------------------------|------------------------|--|
| NAME OF SUBMITTER: | LEONOR RIVERA-HUERTA | |
| SIGNATURE: | /Leonor Rivera-Huerta/ | |
| DATE SIGNED: | D: 07/28/2023 | |

Total Attachments: 8

source=067461-5219-US WO Assignment - SIGNED#page1.tif source=067461-5219-US WO Assignment - SIGNED#page2.tif source=067461-5219-US WO Assignment - SIGNED#page3.tif source=067461-5219-US WO Assignment - SIGNED#page4.tif

PATENT REEL: 064427 FRAME: 0581 508038067

source=067461-5219-US WO Assignment - SIGNED#page5.tif source=067461-5219-US WO Assignment - SIGNED#page6.tif source=067461-5219-US WO Assignment - SIGNED#page7.tif source=067461-5219-US WO Assignment - SIGNED#page8.tif

> PATENT REEL: 064427 FRAME: 0582

WHEREAS, John DESJARLAIS, resident of Pasadena, California, USA, Alex NISTHAL, resident of Monrovia, California, USA and Seung CHU, resident of Upland, California, USA, hereinafter referred to as "Assignors", are inventors of the invention described in the following patent applications:

Title of Invention: HETERODIMERIC ANTIBODIES THAT BIND FIBROBLAST ACTIVATION PROTEIN

U.S. Patent Application No. 16/375,777, filed April 4, 2019; and

International Application No. PCT/US2019/025898, filed April 4, 2019.

WHEREAS, Xencor, Inc., located at 111 West Lemon Avenue, Monrovia, California, 91016 United States of America hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that Assignors will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

| | IN TESTIMONY WHEREOF, Assignor has | s signed his/her name on the date indicated. |
|-------|------------------------------------|---|
| Date: | 9-16-20 | |
| | John DES. | JARLAIS |
| | | |
| | | |
| | IN TESTIMONY WHEREOF, Assignor has | s signed his/her name on the date indicated. |
| Date: | Alex NIST | 'HAL |
| | ARANISI | HAL |
| | | |
| | IN TESTIMONY WHEREOF, Assignor ha | s signed his/her name on the date indicated. |
| Date: | | |
| 25000 | Seung CHU | |
| | | |
| | | |
| | IN TESTIMONY WHEREOF, Assignee ha | s signed his/her name on the dates indicated. |
| | | XENCOR, INC. |
| Date: | By: | |
| | | |
| | Name: | Bassil I. DAHIYAT |
| | Title: | President and Chief Executive Officer |

2 of 2

DB2/ 38147632.2

PATENT REEL: 064427 FRAME: 0584

WHEREAS, John DESJARLAIS, resident of Pasadena, California, USA, Alex NISTHAL, resident of Monrovia, California, USA and Seung CHU, resident of Upland, California, USA, hereinafter referred to as "Assignors", are inventors of the invention described in the following patent applications:

Title of Invention:

HETERODIMERIC ANTIBODIES THAT BIND FIBROBLAST

ACTIVATION PROTEIN

U.S. Patent Application No.

16/375,777, filed April 4, 2019; and

International Application No.

PCT/US2019/025898, filed April 4, 2019.

WHEREAS, Xencor, Inc., located at 111 West Lemon Avenue, Monrovia, California, 91016 United States of America hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that Assignors will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

Assignment
U.S. Patent Application No. 16/375,777
PCT International Application No. PCT/US2019/025898
Attorney Docket No. 067461-5219-US & 067461-5219-WO

| | IN TESTIMONY WHEREOF, Assignor has | s signed his/her name on the date indicated. |
|---------|---|---|
| Date: | John DES. | JARLAIS |
| Date: | IN TESTIMONY WHEREOF, Assignor has | s signed his/her name on the date indicated. HAL |
| Date: | IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated. Date: Seung CHU IN TESTIMONY WHEREOF, Assignee has signed his/her name on the dates indicated. XENCOR, INC. | |
| | | |
| | | |
| Date: _ | Ву: | |
| | Name: | Bassil I. DAHIYAT |
| | Title: | President and Chief Executive Officer |

2 of 2

082/38147632.2

WHEREAS, John DESJARLAIS, resident of Pasadena, California, USA, Alex NISTHAL, resident of Monrovia, California, USA and Seung CHU, resident of Upland, California, USA, hereinafter referred to as "Assignors", are inventors of the invention described in the following patent applications:

Title of Invention:

HETERODIMERIC ANTIBODIES THAT BIND FIBROBLAST ACTIVATION PROTEIN

U.S. Patent Application No.

16/375,777, filed April 4, 2019; and

International Application No. PCT/US2019/025898, filed April 4, 2019.

WHEREAS, Xencor, Inc., located at 111 West Lemon Avenue, Monrovia, California, 91016 United States of America hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that Assignors will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

Assignment
U.S. Patent Application No. 16/375,777
PCT International Application No. PCT/US2019/025898
Attorney Docket No. 067461-5219-US & 067461-5219-WO

| | IN TESTIMONY WHEREOF, Assignor ha | s signed his/her name on the date indicated. |
|---------|-----------------------------------|---|
| Date; | John DES | JARLAIS |
| | IN TESTIMONY WHEREOF, Assignor ha | s signed his/her name on the date indicated. |
| Date: | Alex NIST | HAL |
| Date: | IN TESTIMONY WHEREOF, Assignor ha | |
| | IN TESTIMONY WHEREOF, Assignee ha | s signed his/her name on the dates indicated. |
| | | XENCOR, INC. |
| Date: _ | By: | |
| | Name: | Bassil I. DAHIYAT |
| | Title: | President and Chief Executive Officer |

WHEREAS, John DESJARLAIS, resident of Pasadena, California, USA, Alex NISTHAL, resident of Monrovia, California, USA and Seung CHU, resident of Upland, California, USA, hereinafter referred to as "Assignors", are inventors of the invention described in the following patent applications:

Title of Invention:

HETERODIMERIC ANTIBODIES THAT BIND FIBROBLAST ACTIVATION PROTEIN

U.S. Patent Application No.

16/375,777, filed April 4, 2019; and

International Application No. PCT/US2019/025898, filed April 4, 2019.

WHEREAS, Xencor, Inc., located at 111 West Lemon Avenue, Monroyia, California, 91016 United States of America hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same:

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Leiters Patent and Registrations which may bereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world. and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that Assignors will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignce lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

Assignment
U.S. Patent Application No. 16/375,777
PCT International Application No. PCT/US2019/025898
Attorney Docket No. 067461-5219-US & 067461-5219-WO

| | IN TESTIMONY WHEREOF, Assignor has | signed his/her name on the date indicated. |
|-------|------------------------------------|--|
| Date; | John DESJ | ARLAIS |
| | IN TESTIMONY WHEREOF, Assignor has | signed his/her name on the date indicated. |
| Date: | Alex NISTHAL | |
| Date: | IN TESTIMONY WHEREOF, Assignor has | |
| | Seung CHU | |
| | IN TESTIMONY WHEREOF, Assignee has | |
|)ate: | 25 September 2020 By: _ | XENCOR, INC. |
| | Name: | Bassil I. DAHIYAT |
| | Title: | President and Chief Executive Officer |

2 of 2

DB2/ 38147632.2

RECORDED: 07/28/2023